裸盖菇素如何重塑大脑：治疗益处与风险
摘要
裸盖菇素是一种色胺类化合物，其化学结构与血清素高度相似，主要通过激活血清素2A受体发挥作用，从而触发大脑连接的扩展与Neuroplasticity 神经可塑性。临床试验表明，经过适当规划的一至两次裸盖菇素治疗可显著且持久地改善抑郁症、成瘾及强迫性障碍——其效果往往优于SSRIs（选择性血清素再摄取抑制剂）。然而，治疗效果在很大程度上取决于剂量、身心状态与环境、音乐选择以及疗程后的整合工作。
核心要点
- 裸盖菇素本身并非活性成分 —— 它在肠道中转化为裸盖菇辛，后者穿越血脑屏障，主要激活血清素2A受体。
- 血清素2A受体在前额叶皮质和视觉皮质中高度表达，这解释了裸盖菇素为何会引发视觉幻觉及认知改变。
- 闭上眼睛（佩戴眼罩） 在疗程中至关重要——睁眼会将注意力转向外部幻觉，而非内在处理过程。
- 音乐并非可有可无 —— 疗程中所播放音乐的具体走向（从高潮处逐步递进，再过渡至柔和的自然音效）是驱动认知与情感体验的重要因素。
- 在抑郁症临床试验中，一至两次 25–30mg合成裸盖菇素的疗程所呈现的治疗效果最为显著。
- 裸盖菇素禁用于以下人群：25岁以下者、有精神病、精神分裂症、双相情感障碍或边缘型人格障碍个人史或家族史者。
- 进行临床裸盖菇素治疗前必须停用SSRIs —— 同时使用两者存在潜在危险。
- 大部分积极的大脑重塑发生在疗程结束之后，而非进行过程中 —— 疗程后的时期是关键的Neuroplasticity 神经可塑性窗口期。
- 裸盖菇素能增强大脑连接性并降低模块化程度，使原本不相互通信的脑区之间产生交流 —— 这与治疗效果密切相关。
- 裸盖菇素可重塑对音乐的情感反应，在抑郁症患者中恢复其从音乐中感受喜悦的能力。
详细笔记
裸盖菇素的化学本质
- 裸盖菇素是一种色胺（T-R-Y-P，请勿与”trip”混淆）—— 这一化合物类别还包括DMT和5-MeO-DMT。
- 其化学结构与血清素（5-HT）高度相似，血清素是一种天然存在的神经调质，参与调节情绪、饱腹感、愉悦感、动机、性欲、食欲和睡眠。
- 裸盖菇素本身是一种前体药物 —— 在胃酸的作用下转化为裸盖菇辛。
- 裸盖菇辛穿越血脑屏障，是产生所有效应的真正分子。
- 转化率（以及由此决定的效果持续时间和强度）受胃酸浓度影响，而胃酸浓度又受进食情况的影响。
裸盖菇素在细胞层面的作用机制
- SSRIs是通过多种受体类型广泛提高血清素水平，与之不同，裸盖菇素（通过裸盖菇辛）选择性地与血清素2A（5-HT2A）受体强效结合。
- 5-HT2A受体在新皮质中大量表达，尤其集中于：
- 前额叶皮质（负责情境切换和行为调节）
- 视觉皮质（解释视觉幻觉的产生）
- 其他感觉与知觉脑区
- 这些受体位于锥体神经元的顶端树突上 —— 即向上和横向延伸、与邻近脑区进行通信的突起。
- 激活这些受体会增强原本相对独立、模块化的各脑区之间的横向通信。
裸盖菇素对大脑网络的改变
- 裸盖菇素使大脑从模块化组织（听觉神经元主要与听觉神经元通信等）向各分离脑区之间增强整合的模式转变。
- 这降低了层级化处理的程度 —— 正常情况下，感觉输入按”外周 → 丘脑 → 皮质”的有序序列传导，裸盖菇素则通过丘脑门控变化拓宽这一传导通路。
- 由此产生的结果是：感觉输入（声音、触觉、视觉、内感受）相互融合 —— 即所谓的**synesthesia（联觉）**现象。
- default mode network（默认模式网络）（与自发性思维和白日梦相关）是参与致幻剂作用的多个网络之一。
- 一篇重要论文：“The Effects of Psilocybin and MDMA on Between-Network Resting State Functional Connectivity in Healthy Volunteers”（Carhart-Harris，UCSF）发现，在疗程结束之后，静息态大脑连接性有所增强。
剂量指南
| 形式 | 用量 | 裸盖菇素大致含量 |
|---|---|---|
| 蘑菇 | 1克 | 约10mg裸盖菇素（按1%浓度计算） |
| 蘑菇 | 3.5克（⅛盎司） | 约35mg裸盖菇素 |
| 蘑菇 | 约5克（“英雄剂量”） | 约50mg裸盖菇素 |
| 合成（临床） | 每日1–3mg | 微剂量范围 |
| 合成（临床） | 10mg | 低治疗剂量 |
| 合成（临床） | 25–30mg | 标准治疗剂量（研究最多） |
重要说明： 蘑菇中裸盖菇素的浓度差异较大 —— 根据品种、批次、储存时间和储存方式，浓度可在 0.5%至2% 之间波动。这意味着”1克”剂量实际含有的裸盖菇素可能在5mg至20mg之间。合成裸盖菇素则可消除这一变量。
- 在临床研究中，服用前至少禁食4小时是标准做法，以确保肠道转化的一致性。
治疗性疗程的结构（身心状态与环境）
环境要求：
- 封闭、安全的室内环境 —— 无可开启的窗户、无道路、无明水面
- 全程至少有一名清醒的引导者在场（理想情况下为两名），且引导者不得处于致幻状态
- 受试者全程躺卧，大部分时间佩戴眼罩
- 全程播放音乐
疗程时间线（典型的4–6小时）：
- 起效阶段： 服用后30–45分钟
- 高峰阶段： 情感和知觉强度达到顶峰，常伴有焦虑感 —— 这是ego dissolution（自我消融）的一部分
- 逐渐回落： 约从第2–3小时开始，向第6小时递减
- 疗程后： 常被描述为”乘降落伞归来”
临床试验中使用的音乐走向：
- 早期阶段： 低音量古典音乐，人声极少
- 高峰阶段： 高强度打击乐/鼓点，持续约45–90分钟
- 回落阶段： 较柔和的合唱或旋律性音乐，常以女声为主
- 收尾阶段： 自然音效、环境音频
治疗应用与临床结果
- 根据多项经同行评审的研究，裸盖菇素临床试验在治疗重度抑郁方面的效果显著优于SSRIs。
- 大多数试验采用两次疗程，两次之间间隔一定时间，并在前后均提供支持性后续治疗。
- 已研究的适应症包括：
- Major depression（重度抑郁症）
- Alcohol use disorder（酒精使用障碍） 及其他成瘾症
- OCD（强迫症） 及强迫性障碍
- 进食障碍
- 一项研究（“Increased Low-Frequency Brain Responses to Music After Psilocybin Therapy for Depression”）发现，裸盖菇素恢复了患者对音乐产生积极情感反应的能力 —— 神经影像学确认腹侧被盖区及奖赏回路发生了相应改变。
疗程后的神经可塑性窗口期
- 大部分适应性重塑发生在疗程结束之后，而非进行过程中。
- 裸盖菇素体验结束后，大脑进入Neuroplasticity 神经可塑性高度激活的状态。
- 在此窗口期内开展的活动 —— 包括结构化心理治疗 —— 有助于巩固积极的改变。
- 单纯触发神经可塑性是不够的 ——
English Original 英文原文
How Psilocybin Can Rewire the Brain: Therapeutic Benefits and Risks
Summary
Psilocybin is a tryptamine compound that closely resembles serotonin and works primarily by activating the serotonin 2A receptor, triggering expanded brain connectivity and Neuroplasticity 神经可塑性. Clinical trials have demonstrated that one to two properly structured psilocybin sessions can produce significant and long-lasting improvements in depression, addiction, and compulsive disorders — often outperforming SSRIs. However, therapeutic outcomes depend heavily on dosage, set and setting, music, and post-session integration.
Key Takeaways
- Psilocybin is not the active compound — it converts to psilocin in the gut, which crosses the blood-brain barrier and primarily activates the serotonin 2A receptor.
- The serotonin 2A receptor is highly expressed in the prefrontal cortex and visual cortex, explaining why psilocybin causes visual hallucinations and changes in cognition.
- Eyes closed (with an eye mask) during a session is critical for therapeutic benefit — keeping eyes open redirects attention to external hallucinations rather than internal processing.
- Music is not incidental — the specific contour of music played during a session (building to intensity at the peak, then tapering to soft/nature sounds) is a major driver of the cognitive and emotional experience.
- One to two sessions at 25–30mg psilocybin (synthetic) have shown the most pronounced therapeutic outcomes in clinical trials for depression.
- Psilocybin is contraindicated for people under 25, those with personal or family history of psychosis, schizophrenia, bipolar disorder, or borderline personality disorder.
- SSRIs must be discontinued before clinical psilocybin use — taking both simultaneously is potentially dangerous.
- Much of the positive brain rewiring occurs after the session, not during it — the post-journey period is a critical Neuroplasticity 神经可塑性 window.
- Psilocybin increases brain connectivity and reduces modularity, allowing brain regions that don’t normally communicate to interact — this is linked to therapeutic outcomes.
- Psilocybin can rewire emotional responses to music, restoring the capacity to feel joy from it in people with depression.
Detailed Notes
What Psilocybin Is Chemically
- Psilocybin is a tryptamine (T-R-Y-P, not to be confused with “trip”) — a class that also includes DMT and 5-MeO-DMT.
- Its chemical structure closely resembles serotonin (5-HT), a naturally occurring neuromodulator involved in mood, satiety, pleasure, motivation, libido, appetite, and sleep.
- Psilocybin itself is a prodrug — it is converted to psilocin by the acidity of the gut.
- Psilocin crosses the blood-brain barrier and is the molecule responsible for all effects.
- The conversion rate (and therefore duration/intensity of effects) is influenced by stomach acidity, which is affected by food consumption.
How Psilocybin Works at the Cellular Level
- Unlike SSRIs, which broadly increase serotonin availability across many receptor types, psilocybin (via psilocin) selectively and strongly binds the serotonin 2A (5-HT2A) receptor.
- The 5-HT2A receptor is heavily expressed in the neocortex, particularly:
- The prefrontal cortex (context-switching, behavioral regulation)
- The visual cortex (explaining visual hallucinations)
- Other sensory and perceptual regions
- These receptors are located on the apical dendrites of pyramidal neurons — the branches that extend upward and laterally to communicate with neighboring brain areas.
- Activating these receptors increases lateral communication between brain areas that are normally more modular and separate.
How Psilocybin Changes Brain Networks
- Psilocybin causes a shift from modular brain organization (where auditory neurons mainly talk to auditory neurons, etc.) to increased integration across otherwise separate regions.
- This reduces hierarchical processing — normally, sensory input flows from periphery → thalamus → cortex in an organized sequence. Psilocybin broadens this flow via thalamic gating changes.
- The result: sensory inputs (sound, touch, vision, interoception) become blended — a phenomenon called synesthesia.
- The default mode network (associated with spontaneous thought and daydreaming) is one of several networks implicated in psychedelic action.
- A key paper: “The Effects of Psilocybin and MDMA on Between-Network Resting State Functional Connectivity in Healthy Volunteers” (Carhart-Harris, UCSF) found increased resting-state brain connectivity after sessions had ended.
Dosage Guide
| Form | Amount | Approximate Psilocybin Content |
|---|---|---|
| Mushrooms | 1 gram | ~10mg psilocybin (at 1% concentration) |
| Mushrooms | 3.5g (⅛ oz) | ~35mg psilocybin |
| Mushrooms | ~5 grams (“heroic dose”) | ~50mg psilocybin |
| Synthetic (clinical) | 1–3mg/day | Microdosing range |
| Synthetic (clinical) | 10mg | Low therapeutic dose |
| Synthetic (clinical) | 25–30mg | Standard therapeutic dose (most studied) |
Important caveat: Psilocybin concentration in mushrooms varies widely — from 0.5% to 2% depending on strain, batch, age, and storage. This means a “1 gram” dose could contain anywhere from 5mg to 20mg of actual psilocybin. Synthetic psilocybin eliminates this variability.
- Fasting for at least 4 hours before ingestion is standard in clinical studies to ensure consistent gut conversion.
Structure of a Therapeutic Session (Set and Setting)
Setting requirements:
- A closed, safe indoor environment — no accessible windows to jump from, no roads, no open water
- At least one sober guide present (ideally two) who is not under the influence
- Subject lying down, wearing an eye mask for the majority of the session
- Music playing throughout
Session timeline (typical 4–6 hours):
- Onset: 30–45 minutes after ingestion
- Peak: Maximal emotional and perceptual intensity, often including anxiety — this is part of ego dissolution
- Gradual descent: Starting around hours 2–3, tapering toward hour 6
- Post-session: Often described as “parachuting back in”
Music contour used in clinical trials:
- Early phase: Low-volume, classical music, minimal vocals
- Peak phase: High-intensity percussion/drums, ~45–90 minutes
- Descent phase: Softer, choral or melodic music, often female vocals
- Final phase: Nature sounds, ambient audio
Therapeutic Applications and Clinical Outcomes
- Psilocybin clinical trials are outperforming SSRIs for major depression by significant margins, according to multiple peer-reviewed studies.
- Most trials use two sessions spaced apart with supportive follow-up therapy between and after.
- Conditions studied include:
- Major depression
- Alcohol use disorder and other addictions
- OCD and compulsive disorders
- Eating disorders
- One study (“Increased Low-Frequency Brain Responses to Music After Psilocybin Therapy for Depression”) found psilocybin restored the capacity to feel positive emotional responses to music — with neuroimaging confirming changes in the ventral tegmental area and reward circuitry.
The Post-Session Neuroplasticity Window
- Much of the adaptive rewiring occurs after the session ends, not during it.
- The brain enters a heightened state of Neuroplasticity 神经可塑性 following a psilocybin journey.
- Activities during this window — including structured therapy — can help consolidate positive changes.
- Simply triggering neuroplasticity is not sufficient — the